• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by West Pharmaceutical Services Inc.

    10/23/24 4:56:54 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    S-8 POS 1 tm2426746d1_s8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission October 23, 2024

     

    Registration No. 333-143437

    Registration No. 333-156492

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    West Pharmaceutical Services, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Pennsylvania   23-1210010
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S Employer Identification No.)
         
    530 Herman O. West Dr
    Exton, PA
      19341
    (Address of Principal Executive Offices)   (Zip Code)

     

    West Pharmaceutical Services, Inc. 401 (k) Plan

    West Contract Manufacturing Savings and Retirement Plan

    (Full Title of the Plan)

     

    Kimberly Banks MacKay
    Senior Vice President, General Counsel and Secretary
    West Pharmaceutical Services, Inc.
    530 Herman O. West Drive
    Exton, PA 19341

    (Name and Address of Agent For Service)

     

    (610) 594-2900
    (Telephone Number, Including Area Code, of Agent For Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x  Accelerated filer ¨
    Non-accelerated filer (Do not check if a smaller reporting company) ¨  Smaller reporting company ¨

     

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    West Pharmaceutical Services, Inc., a Pennsylvania corporation (the “Registrant”), is filing this Post-Effective Amendment No. 1 to deregister any and all securities that remain unsold under the Company’s Registration Statements on Form S-8 (Nos. 333-156492 and 333-143437) (the “Registration Statements”), which relate to: (i) the West Pharmaceutical Services, Inc. 401(k) Plan, formerly known as the West Pharmaceutical Services, Inc. Savings Plan; and (ii) The West Contract Manufacturing Savings and Retirement Plan (collectively, the “Plans”). The Registration Statements originally registered an aggregate of 1,550,000 shares (the “Shares”) of common stock of the Registrant, par value $0.25 per share, along with an indeterminate amount of interests (collectively with the Shares, the “Securities”), to be offered and sold pursuant to the Plans.

     

    The Registrant has terminated all offerings of its Securities pursuant to the Plan. Accordingly, the Registrant is filing this Post-Effective Amendment No. 1 to the Registration Statements pursuant to Rule 478 under the Securities Act of 1933, as amended, to remove from registration any and all Securities registered but unsold under the Registration Statements.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing an amendment on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Exton, Commonwealth of Pennsylvania, as of the 23rd day of October, 2024.

     

     

      WEST PHARMACEUTICAL SERVICES, INC.
       
      By: /s/ Kimberly Banks MacKay
        Name: Kimberly Banks MacKay
        Title: Senior Vice President, General Counsel and Secretary

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kimberly Banks MacKay and Ryan Metz, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her in any and all capacities, to sign this Post-Effective Amendment to the Registration Statement on Form S-8 of West Pharmaceutical Services, Inc, and any or all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agent, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment to the Registration Statement on Form S-8 has been

    signed by the following persons in the capacities and on the dates indicated.

     

     

    Signature   Title
         
    /s/ Eric M. Green   Eric M. Green
        President and Chief Executive Officer, Chair of the Board
         
    /s/ Bernard Birkett   Bernard Birkett
        Senior Vice President, Chief Financial Officer
         
    /s/ Mark A. Buthman   Mark A. Buthman
        Director
         
    /s/ William F. Feehery   William F. Feehery
        Director
         
    /s/ Robert F. Friel   Robert F. Friel
        Director
         
    /s/ Thomas W. Hofmann   Thomas W. Hofmann
        Director
         
    /s/ Molly E. Joseph   Molly E. Joseph
        Director
         
    /s/ Deborah L. V. Keller   Deborah L. V. Keller
        Director
         
    /s/ Myla P. Lai-Goldman   Myla P. Lai-Goldman
        Director
         
    /s/ Stephen H. Lockhart   Stephen H. Lockhart
        Director
         
    /s/ Douglas A. Michels   Douglas A. Michels
        Director
         
    /s/ Paolo Pucci   Paolo Pucci
        Director

     

     

     

     

    Get the next $WST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    12/2/2025$285.00Equal-Weight
    Morgan Stanley
    9/15/2025$311.00Buy
    Rothschild & Co Redburn
    6/24/2025$245.00Equal Weight
    Barclays
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    More analyst ratings

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Haugen Janet Brutschea

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    1/5/26 12:37:29 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:33:41 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Finch Norman D. Jr.

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:32:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on West Pharm with a new price target

    Morgan Stanley initiated coverage of West Pharm with a rating of Equal-Weight and set a new price target of $285.00

    12/2/25 8:36:52 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on West Pharm with a new price target

    Rothschild & Co Redburn initiated coverage of West Pharm with a rating of Buy and set a new price target of $311.00

    9/15/25 8:12:22 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.

    SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    10/31/25 11:41:37 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by West Pharmaceutical Services Inc.

    10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 4:14:52 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 7:15:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

    Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system. West Synchrony S1 PFS system provides a broad product po

    1/20/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    5/12/22 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Financials

    Live finance-specific insights

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Declares Quarterly Dividend

    EXTON, Pa., Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug devel

    12/10/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/14/23 12:37:59 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/10/22 8:47:14 AM ET
    $WST
    Medical/Dental Instruments
    Health Care